The potential of ferroptosis inducers (e.g., GPX4 inhibitors or system xc− blockers) is being explored in preclinical models of breast cancer, lung cancer, and melanoma, highlighting its broad applicability in modulating tumor vulnerability and enhancing immune responses [4]. The gene discussed is GPX4; the disease is neoplasm.